2022 DOE Isotope Program User Group Meetings

Below we have compiled information from our 2022 Isotope User Meetings including the recording of each meeting and PDFs of the presentations. To access the recordings, click the links below.

Ac-225
At-211
Ce-134
Pb-203/212

View presentations from the 2022 User Group Meetings below

Actinium-225 Users Group Meeting Presentations

Brookhaven National Laboratory

Ac-225 DOE Isotope Program User Group Meeting by Dr. Cathy Cutler, Brookhaven National Laboratory

RayzeBio

Actinium-225 User Group Meeting by Ken Song M.D., RayzeBio

University of Pittsburgh

Glioma Associated Immune Cells: Potential Targets for Novel Theranostics Molecules by Gary Kohanbash Ph.D, Departments of Neurological Surgery and Immunology University of Pittsburgh

Actinium Pharmaceuticals, Inc.

ATNM US Department of Energy by Monideepa Roy, Ph.D., Actinium Pharmaceuticals, Inc.

Fusion Pharmaceuticals Inc.

Actinium-225 Targeted Radiopharmaceutical Therapy Development by Kevin Roland, Fusion Pharmaceuticals Inc.

Astatine-211 User Group Meeting Presentations

Department of Radiation Oncology School of Medicine ⏐ University of Washington

Astatine-211 DOE Isotope User Group Meeting 2022

Yawen Li, Ph.D.

Department of Radiation Oncology

School of Medicine ⏐ University of Washington

University of Washington

211Astatine production update for the University of Washington

211Astatine production update for the University of Washington

Robert Emery

Cyclotron Institute, Texas A&M University

Cyclotron Institute, Texas A&M University

Steps Forward in Astatine-211

Production and Chemistry at Texas

A&M University

Ionetix

Commercial Production and Distribution of Astatine-211 for Targeted Alpha Therapy Astatine-211 User Group Meeting September 6, 2022 David M. Eve VP, Medical Affairs

Commercial Production and Distribution of Astatine-211 for Targeted Alpha Therapy

David M. Eve

VP, Medical Affairs

Cerium-134 User Group Meeting Presentations

University of Saskatchewan

Cerium 134 as an imaging surrogate for 225Ac

Cerium 134 as an imaging surrogate for 225Ac

Mackenzie Malo, MSc & Kevin Allen, PhD

September 19th, 2022

Cerium-134 DOE Users Meeting

Department of Radiology and Biomedical Imaging, University of California, San Francisco

Efficient chelation of 134Ce/134La using the macrocyclic chelators DOTA and Macropa as potential PET imaging agents

Robert Flavell, MD, PhD Associate Professor

Henry VanBrocklin, PhD Professor

Department of Radiology and Biomedical Imaging, University of California, San Francisco

University of Iowa

Evaluating Tetraazamacrocycle Ligands as 134Ce Chelators

Evaluating Tetraazamacrocycle Ligands as 134Ce Chelators

 

Thaddeus J. Wadas, Ph.D.

Associate Professor of Radiology

University of Iowa

September 19, 2022

Lead-203/212 User Group Meeting Presentations

Oak Ridge National Laboratory

ORNL Ra-224/Pb-212 Generator Production

ORNL Ra-224/Pb-212 Generator Production

Dr Andrew R. Burgoyne

Lead-203/212 Users Group Meeting

October 4th, 2022

RadioMedix

PRE-CLINICAL AND CLINICAL EXPERIENCE WITH TARGETED ALPHA-EMITTER THERAPY

PRE-CLINICAL AND CLINICAL EXPERIENCE WITH TARGETED ALPHA-EMITTER THERAPY

Izabela Tworowska, PhD CSO, RadioMedix

Pacific Northwest National Laboratory

Matthew J. O’Hara presentation

Matthew J. O’Hara, Pacific Northwest National Laboratory 

Viewpoint Molecular Targeting

Viewpoint Molecular Targeting

Memorial Sloan Kettering Cancer Center

David Bauer Pretargeting with Lead-203 and Lead-212

Pretargeting with

Lead-203 and Lead-212

Tuesday, November 1, 2022

David Bauer, Alexa Michel, Spencer Kaminsky, Mengshi Li,

Michael Schultz, Shefali Saini, Suzanne E. Lapi, Jason S. Lewis